Bill dossier · California 2025–26 session · session closed September 30, 2026
Current through · Last editorial review October 1, 2026 · Original snapshot September 18, 2026, 3:00 PM PT (archived below)
SB 1089 — the Preventive Treatment Health Care Act
Final status · recorded October 1, 2026
SIGNED SEPTEMBER 28, 2026SB 1089 was signed on September 28, 2026. Operative: Jan. 1, 2027†. It is law; the chaptered text is the controlling version. Source: California 2026 Final Legislative Ledger.
Archived snapshot — originally current through September 18, 2026, 3:00 PM PTPreserved as originally published. Superseded by the final status above; lifecycle language, deadlines and “pending” states in this section describe the record as it stood on that date, not the current state. The dossier body below (what the bill does, legislative history, analysis and “what happens next”) is the September record.
Senator Laura Richardson · presented to the Governor · sign-or-veto deadline
This measure has been presented to the Governor and awaits action. That is the whole of its current status. Presentment starts a constitutional clock; it creates no obligation, imposes no duty on any party, and is not signature, enactment, chaptering or an effective date.
How this status is established
Senate passage 39–0 on 27 May 2026 and Assembly committee movement are reported. Final Assembly passage and the 3 September presentment are recorded here on owner confirmation and have not been verified against the Legislature’s own history entry; that entry attaches to this record when read. The Governor’s office published signing lists on 22, 27 and 31 August 2026 and none on or after 1 September, and this measure appears on none of them. The accompanying analysis states the same limitation in the same terms.
What is established
JURISDICTION
California, 2025–2026 regular session.
INSTRUMENT
Senate bill. The enrolled text is the controlling version.
LIFECYCLE STATE
PRESENTED. Not law, not operative.
SUBJECT
Medi-Cal prescription drug coverage as it concerns GLP-1 receptor agonist pricing, following the termination of Medi-Cal coverage for weight-loss GLP-1 medicines effective .
PRIMARY SOURCE
What this page does not claim
A clause-by-clause account of the enrolled text is not given here, because the enrolled text has not been read line by line for this page. In particular no negotiation standard, price benchmark, reporting duty or commencement date is restated. Where the measure’s operative language matters to a decision, read the enrolled text directly rather than any summary — including this one.
- Presentment is a recorded event. It is not signature, and a signature would in turn not be an effective date — a chapter number and an operative date are separate facts.
- No party owes anything under this measure today, and nothing in it is in force.
- The Governor’s office published signing lists on 22, 27 and 31 August 2026 and none on or after 1 September. SB 1089 appears on none of them.
Why this measure is tracked here
California published extensive utilization and cost reporting on GLP-1 medicines, then ended Medi-Cal coverage of the weight-loss indication on cost grounds. A measure addressing the pricing of the same drug class belongs on the same record as that decision, so the sequence can be read in one place rather than as unconnected events.
Related: the investigation into what the terminated GLP-1 benefit achieved · the California desk · the Governor’s desk · the patient guide to compounded GLP-1 products · generic-drug regulatory capacity
What would change this page
- Signature, veto, or the lapse of the deadline without signature.
- A chapter number, and separately an effective and an operative date.
- A clause-level read of the enrolled text, at which point the operative provisions can be stated rather than described.
Verification date · presentment confirmed by the site owner; the Legislature’s own history entry is attached to this record when read.